Emergent BioSolutions (EBS) Long-Term Deferred Tax (2010 - 2020)

Emergent BioSolutions' Long-Term Deferred Tax history runs 11 years deep, the most recent figure standing at $17.6 million for Q1 2020.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $17.6 million in Q1 2020; TTM through Mar 2020 was $17.6 million, a N/A change from a year earlier, with the FY2019 full-year figure at $13.4 million, changed 0.0% from the prior year.
• Long-Term Deferred Tax climbed to $17.6 million in Q1 2020 per EBS's latest filing, from $13.4 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $18.2 million in Q2 2016 and bottomed at $2.8 million in Q4 2017.
• The 5-year median for Long-Term Deferred Tax is $12.0 million (2016), against an average of $10.5 million.
• Across the five-year window, Long-Term Deferred Tax slumped 72.39% in 2017 and jumped 378.57% in 2018, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $6.1 million in 2016, then sank by 54.07% to $2.8 million in 2017, then soared by 378.57% to $13.4 million in 2018, then changed by 0.0% to $13.4 million in 2019, then soared by 31.34% to $17.6 million in 2020.
• Per Business Quant, the three latest EBS Long-Term Deferred Tax figures stand at $17.6 million (Q1 2020), $13.4 million (Q4 2019), and $13.4 million (Q4 2018).